The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anti-cancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lymphomas (NHLs), and that the human monoclonal anti-EDB antibody L19 can selectively localize to the lymphoma-associated subendothelial extracellular matrix. In vivo, the preferential accumulation of the antibody at the 
Introduction
Conventional cytotoxic therapies of cancer often do not discriminate between tumor and normal tissues. To achieve therapeutically relevant concentrations in the tumor mass, large drug doses have to be administered to the patient, leading to a poor therapeutic index and unacceptable toxicities to healthy tissues. The selective delivery of therapeutic agents to the tumor site using antibodies against tumor-associated antigens represents a promising strategy to overcome the disadvantages of conventional cancer therapies [1] [2] [3] . Antigens expressed in the tumoral neovasculature are especially attractive targets for antibody-based pharmacodelivery applications due to their inherent accessibility for blood-borne agents [4] [5] [6] . The efficacy of targeting either tumor endothelial cells or the modified sub-endothelial extracellular matrix has been demonstrated in a variety of animal models of solid cancers using antibodies functionalized with different effector moieties 4, [7] [8] [9] [10] [11] [12] [13] [14] , leading to the clinical development of immunocytokines and radioimmunoconjugates for the therapy of solid tumors 6, 15 . Tumortargeting strategies based on the preferential accumulation of biopharmaceuticals around new blood vessels could also be conceivable for the therapy of leukemias and lymphomas, since the dependence of hematologic malignancies on a functional neovasculature has been highlighted already a decade ago 16, 17 .
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with now over 60 000 new cases being diagnosed each year in the United States 18 . The approval of rituximab, a chimeric monoclonal IgG1 antibody specific to CD20, represented a major step towards a more selective and effective therapy of NHLs of B-cell origin. While first shown to be effective in relapsed follicular lymphoma, anti-CD20 immunotherapy is nowadays incorporated in front-line therapy schemes of follicular and diffuse large B-cell lymphoma 18 .
However, in spite of the unquestionable clinical effectiveness of rituximab, a high percentage
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Motivated by the strong anti-neoplastic activity of tumor-targeting immunocytokines in preclinical models of solid cancers [7] [8] [9] [10] 14 , we decided to follow this strategy in mouse models of human B-cell lymphoma. Targeting interleukin-2 (IL-2) to the lymphoma environment was particularly appealing considering several reports in the literature to augment the antibodydependent cellular cytotoxicity (ADCC) of monoclonal antibodies 20, 21 , including rituximab [22] [23] [24] [25] , through co-administration of recombinant IL-2 (rIL-2). Indeed, the importance of ADCC for the in vivo activity of rituximab is strongly supported by the fact that polymorphisms in the IgG Fc receptor FcγRIIIa gene correlate with differential rituximab responsiveness in NHL patients 26, 27 . Natural killer (NK) cells and macrophages, which constitutively express the activating FcγRIIIa receptor that enables them to interact with antibody-coated targets, act as key mediators in this process. However, whereas both preclinical 23, 24 and phase I clinical studies 22, 23, 25 yielded promising results, the ability of rIL-2 to promote NK cell expansion in vivo and enhance rituximab`s ADCC in vitro did not translate into meaningful clinical benefit in a recent phase II study 28 . We hypothesized that a targeted delivery of IL-2 to the lymphoma-associated sub-endothelial matrix, mediating the recruitment of immune effector cells to the lymphoma environment and their local activation at the site of disease, would be superior in improving rituximab`s therapeutic activity compared to the non-targeted administration of free rIL-2.
Our group has a long-standing interest in the targeting of antigens which are selectively expressed in the sub-endothelial matrix of angiogenic blood vessels. The extra domain B (EDB) of fibronectin is one of the best-characterized markers of angiogenesis described so far 29, 30 . This 91-amino acid type III homology domain can be inserted into the fibronectin antibody L19, specific to EDB, has been well established both in animal models of cancer [31] [32] [33] [34] [35] [36] and in patients with solid tumors 37 . However, to the best of our knowledge, there are no reports on EDB-targeting in hematologic malignancies.
In the present study, we investigated the therapeutic performance of the L19-based immunocytokine L19-IL2 in B-cell lymphoma. L19-IL2, which is currently being investigated in multicenter phase II clinical studies in patients with solid tumors, was found to be therapeutically active in monotherapy and dramatically potentiated the efficacy of rituximab in combination therapy experiments in localized and systemic lymphoma models.
The data presented here provide the scientific framework for the clinical evaluation of L19-IL2 in combination with anti-CD20 immunotherapy for the treatment of B-cell malignancies.
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Materials and Methods

Animals and cell lines
The EBV-negative human Burkitt lymphoma cell line Ramos and the murine B-cell lymphoma cell line A20 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). The human follicular lymphoma cell line DoHH-2 was obtained from the German Resource Centre for Biological Material (DSMZ, Braunschweig, Germany). Cells were maintained in log-phase growth in RPMI 1640 medium adjusted to contain 2 mM Lglutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L bicarbonate, 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μ g/mL streptomycin.
Six-to 8-week-old female CB17/lcr SCID and Balb/c mice were obtained from Charles River 
Antibodies and therapeutic agents
L19 is a human monoclonal antibody specific to the EDB domain of fibronectin 35 . The expression, purification and characterization of L19 in SIP format (small immunoprotein, mini-antibody) and the L19-IL2 fusion protein have been described previously 8, 32 . Equimolar amounts of recombinant human IL-2 and L19-IL2 show identical IL-2 activity in the CTLL-2 proliferation assay 8 (Supplemental Figure S1) . Furthermore, the fusion protein displays the same affinity as the parental antibody towards the cognate EDB antigen 8 . The F8 antibody, specific to the extra domain A (EDA) of fibronectin, has been characterized recently 38 . F16 is and analyzed with an Axiovert S100 TV microscope (Zeiss, Feldbach, Switzerland).
Immunohistochemical analysis of EDB expression in human lymphoma samples was performed using biotinylated SIP(L19). In total, twenty-three lymphoma samples, including diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma, as well as three non-neoplastic but inflammatory altered lymph nodes were analyzed. Staining intensity was scored using the four levels "no staining", "weak", "strong" and "very strong", according to published methods 40 .
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Quantitative biodistribution studies
To evaluate the in vivo targeting performance quantitatively, biodistribution analyses using radiolabeled antibody preparations were performed as described before 8 ImageJ software (http://rsb.info.nih.gov/ij/) and expressed as a percentage of measurement area.
Statistical Analysis
Data are expressed as the mean ± SE. Differences in tumor volume between therapeutic groups were compared using the two-tailed Student`s t test. Kaplan-Meier survival curves were performed to display therapeutic efficacy in the disseminated lymphoma model and comparisons were made using the log-rank test. Two-sided P values < 0.05 were considered significant.
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Results
In vitro localization: immunohistochemistry on xenograft tumors
Ramos lymphoma xenografts grown in SCID mice were chosen for the first therapy experiments, since this animal model is frequently used to assess the therapeutic performance of rituximab-based therapeutic strategies. We performed a comparative immunohistochemical analysis of well-characterized antibodies developed in our group, which are currently in clinical development. This analysis included the antibodies L19 (specific to the EDB domain of fibronectin, Fn-EDB) 35 , F8 (EDA domain of fibronectin, Fn-EDA) 38 , and F16 (domain A1
of tenascin C, TnC-A1) 39 . As demonstrated in Figure 1 We evaluated the targeting performance of L19 also in a syngeneic mouse lymphoma model.
To this end, Balb/c mice were challenged i.v. with 2 x 10 6 A20 murine lymphoma cells. 
Therapeutic activity of single-agent L19-IL2 and single-agent rituximab against localized lymphoma xenografts
The recombinant immunocytokine L19-IL2, which is capable of delivering IL-2 to tumoral neovasculature, has exhibited potent anti-cancer activity in various models of solid tumors 8, 15 . To provide information about treatment-associated toxicity, animal weights were measured three times per week. No evidence of toxicity was observed, as in none of the therapy groups mice lost more than 3% of body weight throughout the study period (data not shown).
Therapeutic activity of L19-IL2 in combination with rituximab against localized lymphoma xenografts
Since the magnitude of ADCC-mediated killing of lymphoma cells appears to be an important determinant for the efficacy of rituximab-based therapies 26, 27, 42, 43 , we decided to perform In analogy to the monotherapy experiment, injections were started on day 8 after tumor cell inoculation when palpable Ramos xenografts have developed and repeated every third day for four injections in total.
As shown in Figure 3b , rituximab in combination with unconjugated rIL-2 caused significant tumor growth delay as compared to controls (rIL-2 low and high dose vs. saline: P < 0.001). High dose rIL-2 was more effective in increasing the efficacy of rituximab than low dose rIL-2 (P = 0.038), however, no tumor regressions have been observed and all tumors continued to grow. 
all CRs in the higher dose L19-IL2 group were durable and all mice remained tumor-free for an observation period of one year. Two mice (one in the low dose and one in the high dose L19-IL2 group) did not achieve a CR but the tumor mass was reduced to less than 20 mm 3 .
To investigate whether the therapeutic performance of L19-IL2, alone or in combination, could be reproduced in a second lymphoma model, SCID mice bearing localized DoHH-2 follicular lymphoma xenografts were treated with similar conditions as indicated above (Figure 4) . In analogy to the Ramos model, L19-IL2 was effective as a single-agent in inhibiting lymphoma growth (P < 0.0001), yet without inducing tumor regressions, while the sum of its components in equivalent doses showed no significant therapeutic activity. When combined with rituximab, L19-IL2 reproducibly led to complete tumor eradications in all cases (5/5) with no evidence of relapse at day 48 and was significantly more effective than single-agent rituximab or the combination of rituximab and non-targeted rIL-2 (and naked L19) (P < 0.05), even though 2/5 CRs had been observed in both groups. The therapeutic activity of all agents used against localized Ramos and DoHH-2 xenografts in mono-and combination therapies is summarized in Table 1 .
Importantly, the therapeutic performance of the combination therapies was not associated with additional toxicity. Mice did not exhibit significant loss of body weight at any time point during the treatments (< 3%), indicating that also the combination therapy regimens were well tolerated. The Kaplan-Meier survival curve is shown in Figure 5 . By day 25, all saline-treated control mice succumbed to disseminated disease with a median survival time of 24 days. The administration of unconjugated rIL-2 alone did not exhibit a significant therapeutic benefit (median survival 24 days; P = 0.518, log-rank test). In contrast, the corresponding dose of single-agent L19-IL2 (20 μ g) extended the median survival time to 29 days (P < 0.01, compared to non-targeted rIL-2) and was equally efficient as rituximab in delaying the appearance of the disease compared to saline-treated controls (median survival 29 and 30 days, respectively, vs. 24 days; P < 0.001 for both agents). In combination therapies, the addition of rIL-2 to rituximab delayed the appearance of the disease only slightly compared to and 79, respectively, due to lymphoma development in an axillary lymph node, yet without hind-leg paralysis. The three remaining mice were still disease-free 310 days after tumor cell inoculation.
Analysis of effector cell infiltration and microvascular density
In order to assess the contribution of cytotoxic effector cells to the therapeutic effect of L19-IL2 plus rituximab combination therapy, localized lymphoma xenografts were harvested after two injections and sections were analyzed by immunofluorescence. Figure 6a shows representative tumor sections, stained with the antibody NKp46 specific to a NK cell marker and with the antibody F4/80, which recognizes macrophages. As it is visible in the figure and in the quantitative analysis of tumor-infiltrating effector cells (Figure 6b ), the largest increase in the infiltration of both NK cells and macrophages was observed in the L19-IL2 plus rituximab combination treatment group (7.5-and 2.5-fold increase of NK cell and macrophage infiltration, respectively, compared to saline). By contrast, treatment with unconjugated rIL-2 or with a mixture of the L19-IL2 components was unable to direct 1 9 macrophages or NK cells into lymphoma tissues. Analysis of microvascular density by CD31 staining did not reveal significant differences among the treatment groups (data not shown).
EDB expression in human lymphomas
Facilitated by the fact that L19 binds with equal affinity to murine and human EDB fibronectin, the expression of EDB was confirmed in all human lymphoma entities analyzed, including aggressive and indolent NHLs and Hodgkin lymphomas. Expression of EDB (staining levels weak, strong, or very strong) was observed in 21 out of 23 (91%) lymphoma specimens. Immunoreactivity was generally stronger in aggressive lymphoma subtypes (DLBCL and Burkitt lymphoma, strong or very strong staining levels in 6/8 cases (75%)) as compared to indolent subtypes (FL and CLL, strong or very strong staining levels in 2/7 cases (29%)). Interestingly, while the pattern of staining was strictly vascular in the majority of the cases, a diffuse stromal reaction was observed in some samples. EDB-staining in nonneoplastic but inflammatory altered lymph nodes was undetectable (1/3) or weak (2/3). A selection of immunostainings with the L19 antibody is presented in Figure 7 . Most importantly, when L19-IL2 was co-administered with rituximab, which is used in the clinic for the treatment of the most prevalent forms of NHL, the therapeutic efficacy was dramatically potentiated and long-lasting complete remissions of established xenograft tumors could be achieved, indicative of a strong synergistic effect. Interestingly, L19-IL2 was able to induce complete remissions in the presence of rituximab even at the lowest dose level.
Noteworthy, all mice that achieved a CR following combination therapy with rituximab and the higher dose of L19-IL2 did not experience relapse of the disease after therapy was discontinued, suggesting complete lymphoma eradications in these cases. . At identical doses and schedules as used in the localized Ramos lymphoma model, L19-IL2 was highly efficacious in the presence of rituximab and was able to protect animals from the onset of terminal disease symptoms.
However, it should be noted that the impressive therapeutic effect observed in the animal models used in this study cannot be fully extrapolated to the clinical situation, since SCID mice lack normal B-cells, which also express the target of rituximab. In order to better assess the lymphoma targeting ability of L19-based biopharmaceuticals in the syngeneic setting, we performed quantitative biodistribution studies using the disseminated A20 murine lymphoma model. Combination therapy studies in this model could not be performed, since rituximab does not recognize murine CD20. By contrast, the EDB sequence is identical in mouse and man and the L19 antibody binds with equal affinity to both human and murine EDB fibronectin. Biodistribution analyses with SIP(L19) confirmed the ability of this antibody to efficiently localize on syngeneic lymphomas, with absolute tumor uptake values of 9.3 %ID/g after 24 h and tumor-to-organ ratios of up to 35:1 at 48 h. These targeting results are comparable in magnitude and selectivity with L19 biodistribution data previously published by our group and the group of Luciano Zardi in numerous mouse models of solid cancer 12, 31, 32, 34, 36, 46 .
Repeated administrations of single-agent L19-IL2 to lymphoma-bearing SCID mice were generally well tolerated, as indicated by the absence of weight loss. Most importantly, the coadministration of the immunocytokine with rituximab did not result in cumulative toxicity.
While the tolerability of L19-IL2 in combination with rituximab must eventually be clarified in clinical trials, we were reassured by the fact that L19-IL2 is currently being tested in combination with dacarbazine in patients with melanoma and with gemcitabine in patients with pancreatic cancer.
Mechanistically, L19-IL2 was shown to strongly promote the recruitment of NK cells and macrophages into lymphoma lesions, in analogy with our previous observations obtained from immunocytokine treatments of mice bearing solid tumors 7, 8, 14 . . Furthermore, while a high number of tumor-associated macrophages has been associated with adverse outcome in lymphoma patients treated with chemotherapy only, the prognostic impact of intralesional macrophages is reversed to favorable, when rituximab is added to the treatment regimen 47 .
In principle, the activity of rituximab could be potentiated with other molecular strategies, e.g.
by antibody Fc engineering 48 or glyco-engineering, leading to an increased affinity towards the FcγRIIIa receptor. However, these strategies lead to a more thorough depletion of normal B-lymphocytes and precursors not only from peripheral blood but also from lymph nodes.
Clinical studies are currently investigating the therapeutic potency and tolerability of engineered anti-CD20 antibodies. Potentially, L19-IL2 could display a more selective pattern of effector cell activation in the tumor environment, thanks to its preferential accumulation at the site of disease.
In conclusion, we have demonstrated that IL-2 can be targeted to the sub-endothelial matrix of lymphoma-associated blood vessels, providing a novel and highly effective approach to improve the activity of rituximab without apparent additional toxicities. We believe that our findings justify the clinical evaluation of this unique combination of a tumor-targeting immunocytokine and anti-CD20 immunotherapy for the treatment of B-cell malignancies, which is certainly facilitated by the fact that L19-IL2 is entirely human and already being evaluated in patients with solid tumors. In addition, our results may stimulate the search for other antibody functionalization strategies that hold the promise of a higher single-agent efficacy in the therapy of NHLs. proposed, designed and supervised the project, wrote and revised the manuscript. In contrast, Ramos lymphomas were consistently negative for the large isoforms of tenascin C (using the antibody F16, specific to the domain A1 of human tenascin C, TnC-A1), whereas the glioblastoma displayed a positive staining in the same experiment. For negative controls, the primary antibody was omitted. Scale bars, 100 μ m. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
